Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer
Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), HI Scher(Memorial Hospital), Neal Rosen(Memorial Sloan Kettering Cancer Center), N Timaul(Laboratory of Molecular Genetics), Zhuang Ma, JB Gibbs(United States Military Academy), MM Moasser(Memorial Hospital), Allen Oliff(GlaxoSmithKline (United Kingdom)), N. E. Kohl, G Tjaden(Memorial Hospital)
Cited by 25
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
|Nature|2011|1.4k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k